hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Laminin EGF-like === Beside different types of globular domains each laminin subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminus to that of the EGF-like module. It is also known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the laminin EGF-like domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of laminin EGF-like domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes.
In the autumn of that year, she began studying for a PhD at Newnham College, Cambridge, under the supervision of John Desmond Bernal. It was then that she became aware of the potential of X-ray crystallography to determine the structure of proteins. She was working with Bernal on the technique's first application to the analysis of a biological substance, pepsin. The pepsin experiment is largely credited to Hodgkin, however she always made it clear that it was Bernal who initially took the photographs and gave her additional key insights. Her PhD was awarded in 1937 for research on X-ray crystallography and the chemistry of sterols.
A precarious number of people managed to return to responsible work, while at the other extreme, people were left with severe and disabling impairments. Most people fell into an intermediate group, left with some improvement of their symptoms but also with emotional and intellectual deficits to which they made a better or worse adjustment. On average, there was a mortality rate of approximately 5% during the 1940s. A survey of British lobotomy patients lobotomised between 1942 and 1954 found that 13% of patients were deemed to have made a full recovery and a further 28% were deemed to have made a significant recovery; for 25% lobotomy was deemed to have made no change and 4% died as a result of the surgery. Patients after lobotomy can have a lowering and stabilising of blood pressure. They may have inertia, struggle to complete test problems, and might suffer from metabolic disorders. They may also be considered dispassionate about their feelings because they lack a strong emotional component. It is reported that the patients face less anxiety and stress, but have a constant feel of depression. The frontal lobotomy procedure could have severe negative effects on a patient's personality and ability to function independently. Lobotomy patients often show a marked reduction in initiative and inhibition. They may also exhibit difficulty imagining themselves in the position of others because of decreased cognition and detachment from society. Walter Freeman coined the term "surgically induced childhood" and used it constantly to refer to the results of lobotomy.
Sources: en.wikipedia.org
It would be idle to pretend that the Zionist policy is other than an unpopular one. It has been bitterly attacked in Parliament and is still being fiercely assailed in certain sections of the press. The ostensible grounds of attack are threefold:(1) the alleged violation of the McMahon pledges; (2) the injustice of imposing upon a country a policy to which the great majority of its inhabitants are opposed; and (3) the financial burden upon the British taxpayer ... His covering note asked for a statement of policy to be made as soon as possible and that the cabinet ought to focus on three questions: (1) whether or not pledges to the Arabs conflict with the Balfour declaration; (2) if not, whether the new government should continue the policy set down by the old government in the 1922 White Paper; and (3) if not, what alternative policy should be adopted. Stanley Baldwin, replacing Bonar Law as prime minister, in June 1923 set up a cabinet sub-committee whose terms of reference were:
Peptidomelanin is another water-soluble form of melanin. It was found to be secreted into the surrounding medium by germinating Aspergillus niger (strain: melanoliber) spores. Peptidomelanin release is triggered after exposure to extracellular peptides in the environment. Peptidomelanin is formed as a copolymer between L-DOPA eumelanin and short peptides that form a 'corona', that are responsible for the substance's solubility. The peptide chains are linked to the L-DOPA core polymer via peptide bonds. This led to a proposed biosynthetic process involving the hydroxylation of tyrosinylated or cysteinylated peptides formed via proteases during sporogenesis, which are then incorporated autoxidatively into a growing L-DOPA core polymer. Peptidomelanin is synthesized using a broad-spectrum copper oxidase. This enzyme possesses a type-3 di-copper catalytic centre housed in a large-solvent accessible cavity. This enzyme has been shown to oxidize the thiol groups of cysteinylated peptides, allowing them to copolymerize with an L-DOPA-derived core polymer. Peptidomelanin may also be synthesized using chemical processes.
Rhodesia, officially the Republic of Rhodesia from 1970 onwards, was an unrecognised state in Southern Africa that existed from 1965 to 1979. Rhodesia was the de facto successor to the self-governing colony of Southern Rhodesia following its unilateral declaration of independence (UDI) from the United Kingdom in 1965. Throughout this fourteen-year period, Rhodesia faced internal conflict and political unrest. Following the Lancaster House Agreement in 1979 and general elections held under a universal suffrage in 1980, the territory finally gained de jure independence and international recognition as the Republic of Zimbabwe. The rapid decolonisation of Africa in the late 1950s and early 1960s alarmed a significant proportion of Southern Rhodesia's white population. In an effort to delay the transition to black majority rule, the white Southern Rhodesian cabinet issued a unilateral declaration of independence (UDI) from the United Kingdom on 11 November 1965. The new nation, renamed Rhodesia, initially sought recognition as an autonomous realm within the Commonwealth of Nations, but reconstituted itself as a republic in 1970. Following the UDI, the United Nations Security Council passed resolution 216 which called upon all states to deny recognition and assistance to Rhodesia. Two far-left African nationalist parties, the Zimbabwe African People's Union (ZAPU) and Zimbabwe African National Union (ZANU), launched an armed insurgency against the government after the UDI, sparking the Rhodesian Bush War.
OCT was the first cyclooctyne developed for Cu-free click chemistry. While linear alkynes are unreactive at physiological temperatures, OCT was able readily react with azides in biological conditions while showing no toxicity. However, it was poorly water-soluble, and the kinetics were barely improved over the Staudinger ligation. ALO (aryl-less octyne) was developed to improve water solubility, but it still had poor kinetics. Monofluorinated (MOFO) and difluorinated (DIFO) cyclooctynes were created to increase the rate through the addition of electron-withdrawing fluorine substituents at the propargylic position. Fluorine is a good electron-withdrawing group in terms of synthetic accessibility and biological inertness. In particular, it cannot form an electrophilic Michael acceptor that may side-react with biological nucleophiles. DIBO (dibenzocyclooctyne) was developed as a fusion to two aryl rings, resulting in very high strain and a decrease in distortion energies. It was proposed that biaryl substitution increases ring strain and provides conjugation with the alkyne to improve reactivity. Although calculations have predicted that mono-aryl substitution would provide an optimal balance between steric clash (with azide molecule) and strain, monoarylated products have been shown to be unstable. BARAC (biarylazacyclooctynone) followed with the addition of an amide bond which adds an sp2-like center to increase rate by distortion. Amide resonance contributes additional strain without creating additional unsaturation which would lead to an unstable molecule.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.